FDA Approves Wegovy to Treat Serious Liver Disease

Follow Drugslib on

By I. Edwards HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 20, 2025.

via HealthDay

WEDNESDAY, Aug. 20, 2025 — The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s popular weight-loss drug Wegovy to treat a serious form of fatty liver disease.

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S. adults — or roughly 6% of the population — have the condition, according to the FDA.

“Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide,” Dr. Martin Holst Lange, Novo Nordisk’s chief scientific officer and head of research and development, told The Wall Street Journal.

Wegovy is best known as a once-weekly injection used for weight loss, but clinical trials have shown it may benefit people with other serious health conditions.

The FDA has also approved the drug to lower the risk of cardiovascular events, like heart attacks, in high-risk patients, The Wall Street Journal said.

Novo Nordisk’s sister drug Ozempic, which shares the same active ingredient — semaglutide — is already approved for diabetes.

The FDA decision was based on results from a late-stage clinical trial showing Wegovy’s effectiveness in treating MASH.

Novo Nordisk said it is using the same data in applications for approval in the European Union and Japan.

MASH, previously known as NASH, occurs when fat builds up in the liver and causes inflammation and scarring. If left untreated, it can lead to liver failure or cancer, The Cleveland Clinic says.

Sources

  • The Wall Street Journal, Aug. 18, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-08-21 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords